Diagnostic Value of Anti-GBV-C Antibodies in HIV-Infected Patients

Chemical Biology and Drug Design

Volumn 78, Issue 2, 2011, Pages 277-282

  Gómara, Maria J ^a   Fernández, Leticia ^a   Pérez, Teresa ^a   Tenckhoff, Solveig ^b   Casanovas, Aurora ^c   Tillmann, Hans L ^b,d   Haro, Isabel ^a  

^a INSTITUTE OF ADVANCED CHEMISTRY OF CATALONIA IQAC CSIC   (Spain)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

GB virus C; Hepatitis C virus; Human immunodeficiency virus; Human immunodeficiency virus diagnosis; Immunoassays; Peptides

Indexed keywords

BIOLOGICAL MARKER; CHIMERIC ANTIBODY; SYNTHETIC PEPTIDE; VIRUS ANTIBODY;

ANTIBODY DETECTION; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FLAVIVIRUS INFECTION; HEMODIALYSIS; HEPATITIS G VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SAMPLE; SENSITIVITY AND SPECIFICITY; SERUM;

ANTIBODIES, VIRAL; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GB VIRUS C; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HUMANS;

GB VIRUS C; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 79960364760     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01143.x     Document Type: Article

References (26)

1. Leary T.P., Muerhoff A.S., Simons J.N., Pilot-Matias T.J., Erker J.C., Chalmers M.L., Schlander G.G., Dawson G.J., Desai S.M., Mushahwar I.K. (1996) Sequence and genomic organization of GBV-C: a novel member of the flaviviridae associated with human Non-A-E hepatitis. J Med Virol;48:60-67.
2. Linnen J., Wages J. Jr, Zhang-Keck Z.Y., Fry K.E., Krawczynski K.Z., Alter H., Koonin E. et al. (1996) Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science;271:505-508.
3. Kaiser T., Tillmann H.L. (2005) GB virus C infection: is there a clinical relevance for patients infected with the human immunodeficiency virus? AIDS Rev;7:3-12.
4. Shankar E.M., Solomon S.S., Vignesh R., Murugavel K.G., Sundaram M., Solomon S., Balakrishnan P., Kumarasamy N. (2008) GB virus infection: a silent anti-HIV panacea within? Trans R Soc Trop Med Hyg;102:1176-1180.
5. Tacke M., Schmolke S., Schlueter V., Sauleda S., Esteban J.I., Tanaka E., Kiyosawa K., Alter H.J., Schmitt U., Hess G., Ofenloch-Haehnte B., Engel A.M. (1997) Humoral immune response to the E2 protein of hepatitis G virus is associated with long-term recovery from infection and reveals a high frequency of hepatitis G virus exposure among healthy blood donors. Hepatology;26:1626-1633.
6. Tanaka E., Kiyosawa K., Shimoda K., Hino K., Tacke M., Schmolke S., Engel A.M., Hess G. (1998) Evolution of hepatitis G virus infection and antibody response to envelope protein in patients with transfusion-associated non-A, non-B hepatitis. J Viral Hepat;5:153-159.
7. Silini E., Belli L., Alberti A.B., Asti M., Cerino A., Bissolati M., Rondinara G., De Carlis L., Forti D., Mondelli M.U., Ideo G. (1998) HGV/GBV-C infection in liver transplant recipients: antibodies to the viral E2 envelope glycoprotein protect from de novo infection. J Hepatol;29:533-540.
8. Tillmann H.L., Heringlake S., Trautwein C., Meissner D., Nashan B., Schlitt H.J., Kratochvil J., Hunt J., Qiu X., Lou S.C., Pichuiayr R., Manns M.P. (1998) Antibodies against the GB virus C envelope 2 protein before liver transplantation protect against GB virus C de novo infection. Hepatology;28:379-384.
9. Tillmann H.L., Heiken H., Knapik-Botor A., Heringlake S., Ockenga J., Wilber J.C., Goergen B., Detmer J., McMorrow M., Stoll M., Schmidt R.E., Manns M.P. (2001) Infection with GB virus C and reduced mortality among HIV-infected patients. N Eng J Med;345:715-724.
10. Kao J.H., Chen P.J., Chen W., Hsiang S.C., Lai M.Y., Chen D.S. (1997) Amplification of GB virus-C hepatitis G virus RNA with primers from different regions of the viral genome. J Med Virol;51:284-289.
11. Pilot-Matias T.J., Carrick R.J., Coleman P.F., Leary T.P., Surowy T.K., Simons J.N., Muerhoff A.S., Buijk S.L., Chalmers M.L., Dawson G.J., Desai S.M., Mushahwar I.K. (1996) Expression of the GB virus C E2 glycoprotein using the Semliki Forest virus vector system and its utility as a serologic marker. Virology;225:282-292.
12. Tacke M., Kiyosawa K., Stark K., Schlueter V., Ofenloch-Haehnle B., Hess G., Engel A.M. (1997) Detection of antibodies to a putative hepatitis G virus envelope protein. Lancet;349:318-320.
13. Gomara M.J., Fernandez L., Perez T., Ercilla G., Haro I. (2010) Assessment of synthetic chimeric multiple antigenic peptides for diagnosis of GB virus C infection. Anal Biochem;396:51-58.
14. Huang C.F., Lin S.S., Ho Y.C., Chen F.L., Yang C.C. (2006) The immune response induced by hepatitis B virus principal antigens. Cell Mol Immunol;3:97-106.
15. Gretch D.R. (1997) Use and interpretation of HCV diagnostic tests in the clinical setting. Clin Liver Dis;1:543-557.
16. Fontvila O., Mestres C., Muñoz M., Haro I., Alsina M.A., Pujol M. (2008) Surface behaviour and peptide-lipid interactions of the E1(3-17)R and E1(3-17)G peptides from E1 capside protein of GBV-C/HGV virus. Colloids Surf A Physicochem Eng Asp;321:175-180.
17. Larios C., Busquets M.A., Carilla J., Alsina M.A., Haro I. (2004) Effects of overlapping GB virus C/Hepatitis G virus synthetic peptides on biomembrane models. Langmuir;20:11149-11160.
18. Larios C., Christiaens B., Gomara M.J., Alsina M.A., Haro I. (2005) Interaction of synthetic peptides corresponding to hepatitis G virus (HGV/GBV-C) E2 structural protein with phospholipid vesicles. FEBS J;272:2456-2466.
19. Rojo N., Ercilla G., Haro I. (2003) GB virus C (GBV-C) hepatitis G virus (HGV): towards the design of synthetic peptides-based biosensors for immunodiagnosis of GBV-C/HGV infection. Curr Protein Pept Sci;4:291-298.
20. Perez T., Ercilla G., Chan W.C., Haro I. (2006) Antigenicity of chimeric and cyclic synthetic peptides based on nonstructural proteins of GBV-C/HGV. J Pept Sci;12:267-278.
21. Berzsenyi M.D., Bowden D.S., Kelly H.A., Watson K.M., Mijch A.M., Hammond R.A., Crowe S.M., Roberts S.K. (2007) Reduction in hepatitis C-related liver disease associated with GB virus C in human immunodeficiency virus coinfection. Gastroenterology;133:1821-1830.
22. Baggio-Zappia G.L., Hernandes Granato C.F. (2009) HIV-GB virus C co-infection: an overview. Clin Chem Lab Med;47:12-19.
23. Barbosa A.D.J., Baggio-Zappia G.L., Dobo C., Alves-Sousa V.K., Lanzara G.D.A., Da Silva I.D.C.G., Lanzoni V.P., Granato C.F.H. (2009) Analysis of GB virus C infection among HIV-HCV coinfected patients. Rev Soc Bras Med Trop;42:591-593.
24. Tillmann H.L., Manns M.P. (2001) GB virus-C infection in patients infected with the human immunodeficiency virus. Antiviral Res;52:83-90.
25. Rodriguez B., Woolley I., Lederman M.M., Zdunek D., Hess G., Valdez H. (2003) Effect of GB virus C coinfection on response to antiretroviral treatment in human immunodeficiency virus-infected patients. J Infect Dis;187:504-507.
26. Tillmann H.L., Kaiser T., Fox Z., Staszewski S., Antunes F., Monforte A.D., Vemazza P., Hill A., Dragsted U.B., Lundgren J.D. (2005) Impact of coinfection with HIV-1 and GB Virus C in patients receiving a ritonavir-boosted HAART regimen: a substudy to the MaxCmin1 trial [2]. J Acquir Immune Defic Syndr;40:378-380.